{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T08:14:37Z","timestamp":1768464877023,"version":"3.49.0"},"reference-count":24,"publisher":"Archives of Endocrinology and Metabolism","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,6]]},"DOI":"10.20945\/2359-4292-2024-0159","type":"journal-article","created":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T17:53:17Z","timestamp":1731001997000},"source":"Crossref","is-referenced-by-count":4,"title":["Single zoledronic acid infusion as a cause of acute kidney impairment requiring dialysis in two patients with osteoporosis"],"prefix":"10.20945","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0367-9114","authenticated-orcid":false,"given":"Djordje","family":"Marina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3162-0793","authenticated-orcid":false,"given":"Charlotte","family":"Ejersted","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3222-0748","authenticated-orcid":false,"given":"Kristine","family":"Hommel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0483-8594","authenticated-orcid":false,"given":"Peter","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"8510","reference":[{"key":"key20241107175310_B1","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.bonr.2018.06.007","article-title":"Bisphosphonate conjugation for bone specific drug targeting","volume":"9","author":"Farrell","year":"2018","unstructured":"1 Farrell KB, Karpeisky A, Thamm DH, Zinnen S. Bisphosphonate conjugation for bone specific drug targeting. Bone Rep. 2018;9:47-60. doi: 10.1016\/j.bonr.2018.06.007.","journal-title":"Bone Rep"},{"issue":"10001","key":"key20241107175310_B2","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S0140-6736(15)60908-4","article-title":"Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials","volume":"386","author":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG)","year":"2015","unstructured":"2 Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG). Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet. 2015;386(10001):1353-61. doi: 10.1016\/S0140-6736(15)60908-4.","journal-title":"Lancet"},{"issue":"11","key":"key20241107175310_B3","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1038\/ki.2008.356","article-title":"Bisphosphonate nephrotoxicity","volume":"74","author":"Perazella","year":"2008","unstructured":"3 Perazella MA, Markowitz GS. Bisphosphonate nephrotoxicity. Kidney Int. 2008;74(11):1385-93. doi: 10.1038\/ki.2008.356.","journal-title":"Kidney Int"},{"issue":"2","key":"key20241107175310_B4","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","unstructured":"4 Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239-45. doi: 10.1038\/clpt.1981.154.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"key20241107175310_B5","first-page":"154","article-title":"Early onset acute tubular necrosis following single infusion of zoledronate","volume":"13","author":"Yachoui","year":"2016","unstructured":"5 Yachoui R. Early onset acute tubular necrosis following single infusion of zoledronate. Clin Cases Miner Bone Metab. 2016;13(2):154-6. doi: 10.11138\/ccmbm\/2016.13.2.154.","journal-title":"Clin Cases Miner Bone Metab"},{"issue":"2","key":"key20241107175310_B6","doi-asserted-by":"crossref","first-page":"E289","DOI":"10.1097\/MJT.0000000000000702","article-title":"Severe Acute Kidney Injury after Single-Dose Injection of Zoledronic Acid in an Elderly Patient","volume":"25","author":"Im","year":"2018","unstructured":"6 Im H, Choi HM, Oh DJ, Kwon YE. Severe Acute Kidney Injury after Single-Dose Injection of Zoledronic Acid in an Elderly Patient. Am J Ther. 2018;25(2):E289-90. doi: 10.1097\/MJT.0000000000000702.","journal-title":"Am J Ther"},{"issue":"6","key":"key20241107175310_B7","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.nefro.2017.03.006","article-title":"Insuficiencia renal por nefropat\u00eda tubulointersticial con tubulopat\u00eda proximal tipo Fanconi tras tratamiento con \u00e1cido zoledr\u00f3nico","volume":"37","author":"Guti\u00e9rrez S\u00e1nchez","year":"2017","unstructured":"7 Guti\u00e9rrez S\u00e1nchez MJ, Petkov Stoyanov V, Pedraza Cez\u00f3n L, Mart\u00edn Navarro JA. Insuficiencia renal por nefropat\u00eda tubulointersticial con tubulopat\u00eda proximal tipo Fanconi tras tratamiento con \u00e1cido zoledr\u00f3nico. Nefrolog\u00eda. 2017;37(6):660-1. doi: 10.1016\/j.nefro.2017.03.006.","journal-title":"Nefrolog\u00eda"},{"issue":"12","key":"key20241107175310_B8","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1507\/endocrj.EJ12-0166","article-title":"A case of zoledronate-induced tubulointerstitial nephritis with Fanconi syndrome","volume":"59","author":"Torimoto","year":"2012","unstructured":"8 Torimoto K, Okada Y, Arao T, Mori H, Tanaka Y. A case of zoledronate-induced tubulointerstitial nephritis with Fanconi syndrome. Endocr J. 2012;59(12):1051-6. doi: 10.1507\/endocrj.EJ12-0166.","journal-title":"Endocr J"},{"issue":"9","key":"key20241107175310_B9","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.2169\/internalmedicine.50.4855","article-title":"A case of acquired Fanconi syndrome induced by zoledronic acid","volume":"50","author":"Yoshinami","year":"2011","unstructured":"9 Yoshinami T, Yagi T, Sakai D, Sugimoto N, Imamura F. A case of acquired Fanconi syndrome induced by zoledronic acid. Intern Med. 2011;50(9):1075-9. doi: 10.2169\/internalmedicine.50.4855.","journal-title":"Intern Med"},{"issue":"7","key":"key20241107175310_B10","first-page":"867","article-title":"A case of fanconi syndrome induced by zoledronic acid in a metastatic colorectal cancer patient","volume":"42","author":"Okagawa","year":"2015","unstructured":"10 Okagawa Y, Sato Y, Onuma H, Osuga T, Hayashi T, Sato T, et al. A case of fanconi syndrome induced by zoledronic acid in a metastatic colorectal cancer patient. Japanese J Cancer Chemother. 2015;42(7):867-70.","journal-title":"Japanese J Cancer Chemother"},{"issue":"9","key":"key20241107175310_B11","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1111\/bcp.14780","article-title":"Bisphosphonate nephropathy: A case series and review of the literature","volume":"87","author":"de Roij van Zuijdewijn","year":"2021","unstructured":"11 de Roij van Zuijdewijn C, van Dorp W, Florquin S, Roelofs J, Verburgh K. Bisphosphonate nephropathy: A case series and review of the literature. Br J Clin Pharmacol. 2021;87(9):3485-91. doi: 10.1111\/bcp.14780.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"key20241107175310_B12","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1046\/j.1523-1755.2003.00071.x","article-title":"Toxic acute tubular necrosis following treatment with zoledronate (Zometa)","volume":"64","author":"Markowitz","year":"2003","unstructured":"12 Markowitz GS, Fine PL, Stack JI, Kunis CL, Radhakrishnan J, Palecki W, et al. Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int. 2003;64(1):281-9. doi: 10.1046\/j.1523-1755.2003.00071.x.","journal-title":"Kidney Int"},{"issue":"17","key":"key20241107175310_B13","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJM200310233491721","article-title":"Renal Failure with the Use of Zoledronic Acid","volume":"349","author":"Chang","year":"2003","unstructured":"13 Chang JT, Green LBJ. Renal Failure with the Use of Zoledronic Acid. N Engl J Med. 2003;349(17):1676-9. doi: 10.1056\/nejm200310233491721.","journal-title":"N Engl J Med"},{"issue":"7-8","key":"key20241107175310_B14","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1345\/aph.1E589","article-title":"Zoledronic acid and renal toxicity: Data from French adverse effect reporting database","volume":"39","author":"Munier","year":"2005","unstructured":"14 Munier A, Gras V, Andrejak M, Bernard N, Jean-Pastor MJ, Gautier S, et al. Zoledronic acid and renal toxicity: Data from French adverse effect reporting database. Ann Pharmacother. 2005;39(7-8):1194-7. doi: 10.1345\/aph.1E589.","journal-title":"Ann Pharmacother"},{"issue":"2","key":"key20241107175310_B15","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/8756-3282(95)00445-9","article-title":"Bisphosphonates: A review of their pharmacokinetic properties","volume":"18","author":"Lin","year":"1996","unstructured":"15 Lin JH. Bisphosphonates: A review of their pharmacokinetic properties. Bone. 1996;18(2):75-85. doi: 10.1016\/8756-3282(95)00445-9.","journal-title":"Bone"},{"key":"key20241107175310_B16","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1634\/theoncologist.10-90001-3","article-title":"Preclinical Perspectives on Bisphosphonate Renal Safety","volume":"10","author":"Body","year":"2005","unstructured":"16 Body JJ, Pfister T, Bauss F. Preclinical Perspectives on Bisphosphonate Renal Safety. Oncologist. 2005;10(S1):3-7. doi: 10.1634\/theoncologist.10-90001-3.","journal-title":"Oncologist"},{"issue":"9","key":"key20241107175310_B17","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa011807","article-title":"Intravenous Zoledronic Acid in Postmenopausal Women with Low Bone Mineral Density","volume":"346","author":"Reid","year":"2002","unstructured":"17 Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, et al. Intravenous Zoledronic Acid in Postmenopausal Women with Low Bone Mineral Density. N Engl J Med. 2002;346(9):653-61. doi: 10.1056\/nejmoa011807.","journal-title":"N Engl J Med"},{"issue":"18","key":"key20241107175310_B18","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis","volume":"356","author":"Black","year":"2007","unstructured":"18 Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, et al. Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis. N Engl J Med. 2007;356(18):1809-22. doi: 10.1056\/nejmoa067312.","journal-title":"N Engl J Med"},{"issue":"18","key":"key20241107175310_B19","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJMoa074941","article-title":"Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture","volume":"357","author":"Lyles","year":"2007","unstructured":"19 Lyles KW, Col\u00f3n-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, et al. Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture. N Engl J Med. 2007;357(18):1799-809. doi: 10.1056\/nejmoa074941.","journal-title":"N Engl J Med"},{"issue":"5","key":"key20241107175310_B20","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/ki.2008.193","article-title":"Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women","volume":"74","author":"Boonen","year":"2008","unstructured":"20 Boonen S, Sellmeyer DE, Lippuner K, Orlov-Morozov A, Abrams K, Mesenbrink P, et al. Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women. Kidney Int. 2008;74(5):641-8. doi: 10.1038\/ki.2008.193.","journal-title":"Kidney Int"},{"issue":"1","key":"key20241107175310_B21","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1006\/abbi.1999.1502","article-title":"Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase","volume":"373","author":"Bergstrom","year":"2000","unstructured":"21 Bergstrom JD, Bostedor RG, Masarachia PJ, Reszka AA, Rodan G. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys. 2000;373(1):231-41. doi: 10.1006\/ABBI.1999.1502.","journal-title":"Arch Biochem Biophys"},{"issue":"4","key":"key20241107175310_B22","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.tiv.2008.01.006","article-title":"Preclinical evidence for nitrogen-containing bisphosphonate inhibition of farnesyl diphosphate (FPP) synthase in the kidney: implications for renal safety","volume":"22","author":"L\u00fche","year":"2008","unstructured":"22 L\u00fche A, K\u00fcnkele KP, Haiker M, Schad K, Zihlmann C, Bauss F, et al. Preclinical evidence for nitrogen-containing bisphosphonate inhibition of farnesyl diphosphate (FPP) synthase in the kidney: implications for renal safety. Toxicol In Vitro. 2008;22(4):899-909. doi: 10.1016\/J.TIV.2008.01.006.","journal-title":"Toxicol In Vitro"},{"issue":"1","key":"key20241107175310_B23","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.bone.2010.12.024","article-title":"The kidney and bisphosphonates","volume":"49","author":"Miller","year":"2011","unstructured":"23 Miller PD. The kidney and bisphosphonates. Bone. 2011;49(1):77-81. doi: 10.1016\/J.BONE.2010.12.024.","journal-title":"Bone"},{"issue":"25","key":"key20241107175310_B24","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000020831","article-title":"Effect of different hydration doses on renal function in patients with primary osteoporosis treated with zoledronic acid: A hospital-based retrospective cohort study","volume":"99","author":"Dai","year":"2020","unstructured":"24 Dai X, Deng Y, Luo Y, Xie J, Ma H. Effect of different hydration doses on renal function in patients with primary osteoporosis treated with zoledronic acid: A hospital-based retrospective cohort study. Medicine (Baltimore). 2020;99(25):E20831. doi: 10.1097\/MD.0000000000020831.","journal-title":"Medicine (Baltimore)"}],"container-title":["Archives of Endocrinology and Metabolism"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T17:53:23Z","timestamp":1731002003000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aem-sbem.com\/article\/single-zoledronic-acid-infusion-as-a-cause-of-acute-kidney-impairment-requiring-dialysis-in-two-patients-with-osteoporosis\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":24,"alternative-id":["10.20945\/2359-4292-2024-0159"],"URL":"https:\/\/doi.org\/10.20945\/2359-4292-2024-0159","relation":{},"ISSN":["2359-3997","2359-4292"],"issn-type":[{"value":"2359-3997","type":"print"},{"value":"2359-4292","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]},"article-number":"e240159"}}